756 results on '"Brentjens, Renier J"'
Search Results
2. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
3. Author Correction: T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection
4. Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors
5. Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant
6. CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function
7. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
8. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
9. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
10. Multipurposing CARs: Same engine, different vehicles
11. Engineering CAR-T cells to activate small-molecule drugs in situ
12. Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
13. Developing a membrane-proximal CD33-targeting CAR T cell
14. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia
15. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models
16. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells
17. Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing
18. Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy
19. CAR T cell therapy: looking back and looking forward
20. Chimeric Antigen Receptor-T Cells for Leukemias in Adults: Methods, Data and Challenges
21. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management
22. Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response
23. Engineering strategies to overcome the current roadblocks in CAR T cell therapy
24. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
25. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
26. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells
27. Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience
28. Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy
29. Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector
30. Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center
31. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia
32. Development of CAR T cells designed to improve antitumor efficacy and safety
33. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages
34. Application of CAR T cells for the treatment of solid tumors
35. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
36. Supplementary Figure Legends from Optimization of T-cell Receptor–Modified T Cells for Cancer Therapy
37. Data from Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells
38. Supplementary Figure Legends from Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells
39. Figure S4 from Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells
40. Data from Optimization of T-cell Receptor–Modified T Cells for Cancer Therapy
41. Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
42. Supplementary Figures 1-8 from Optimization of T-cell Receptor–Modified T Cells for Cancer Therapy
43. Supplementary Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
44. Data from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
45. Supplementary Figures from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
46. Data from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
47. Figure S1, Figure S2, Figure S3, Figure S4 from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
48. Supplementary Material from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
49. Supplementary Tables from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
50. Table S1, Table S2, Table S3, Table S4 from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.